Home > Boards > US Listed > Biotechs > Amarin Corp. PLC ADS (AMRN)

Kiwi..2028 is a good deal for everyone.

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (3) | Next 10 | Previous | Next
postes Member Profile
Member Level 
Followed By 7
Posts 2,123
Boards Moderated 0
Alias Born 03/01/07
160x600 placeholder
Amarin Supports Investigator-Initiated Trial at Kaiser Permanente in the U.S. to Study the Effects of VASCEPA® (icosapent et... GlobeNewswire Inc. - 8/7/2020 12:12:27 PM
Amarin Announces Plans to Maximize Blockbuster Potential of VASCEPA® (icosapent ethyl) in Europe GlobeNewswire Inc. - 8/4/2020 6:30:26 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 8/4/2020 6:17:36 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/4/2020 6:11:39 AM
Amarin Reports Second Quarter 2020 Financial Results and Provides Update on Operations GlobeNewswire Inc. - 8/4/2020 6:00:10 AM
VASCEPA® (icosapent ethyl) Data from REDUCE-IT® REVASC, Including New Data on Timeframe to Demonstrated Benefit, Presented ... GlobeNewswire Inc. - 7/27/2020 7:00:10 AM
Amarin to Report Second Quarter 2020 Results and Host Conference Call on August 4, 2020 GlobeNewswire Inc. - 7/21/2020 4:15:10 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 7/14/2020 5:20:47 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/16/2020 5:29:34 PM
Amarin Announces Patent Litigation Settlement Agreement with Apotex Inc. GlobeNewswire Inc. - 6/16/2020 4:30:10 PM
VASCEPA® (icosapent ethyl) Shows Significant Cardiovascular Risk Reduction in People with Diabetes in Prespecified and Post ... GlobeNewswire Inc. - 6/15/2020 7:00:10 AM
Proxy Statement (definitive) (def 14a) Edgar (US Regulatory) - 6/1/2020 4:15:58 PM
Amarin Plans to Increase VASCEPA® (icosapent ethyl) Promotion and Education GlobeNewswire Inc. - 6/1/2020 7:00:10 AM
Amarin Supports Trial to Investigate the Effects of VASCEPA® (icosapent ethyl) in the Treatment of COVID-19 GlobeNewswire Inc. - 5/21/2020 4:05:10 PM
VASCEPA® (icosapent ethyl) Shows Significant Reduction in Coronary Revascularization, Including Coronary Stenting and Cardia... GlobeNewswire Inc. - 5/14/2020 2:50:10 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/8/2020 5:19:58 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 4/30/2020 6:39:17 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 4/30/2020 6:32:26 AM
Amarin Reports First Quarter 2020 Financial Results and Provides Update on Operations GlobeNewswire Inc. - 4/30/2020 5:00:10 AM
Amended Annual Report (10-k/a) Edgar (US Regulatory) - 4/29/2020 4:12:49 PM
Amarin to Report First Quarter 2020 Results and Host Conference Call on April 30, 2020 GlobeNewswire Inc. - 4/28/2020 7:00:10 AM
Cannabis? CBD? That's Old News, A New Sector Bull Run Has Begun InvestorsHub NewsWire - 4/16/2020 8:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 4/13/2020 4:37:32 PM
Amarin to Host Conference Call on April 13, 2020 to Provide Preliminary First Quarter 2020 Results and Operational Update GlobeNewswire Inc. - 4/8/2020 4:05:10 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 3/31/2020 9:23:01 AM
postes Member Level  Sunday, 06/28/20 04:24:00 PM
Re: Whalatane post# 283448
Post # of 290556 
Kiwi..2028 is a good deal for everyone.

1.the market is built up substantially more for the H&R.

2.AMRN will spend the money to promote..it's not just DTC but 800 sales reps and maybe more...AMRN can realize some profit ( read the story of the little red hen)

3.H&R get a 6 month lead which is a huge deal...in six months H&R will have placement in all the Biggie's...how many different generics of the same drug do you think Walgreens carries?

4.AMRN will have a bright future and start looking at other indications without the generics looking over their back.

5. The stock Price..oh the stock price.

6..the board will figure something else to debate to the nth degree.

7.last but not least CVD will have a super star drug.



Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (3) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist